EP Patent

EP1525890A1 — Protein-Proteophore complexes

Assigned to Ascendis Pharma GmbH · Expires 2005-04-27 · 21y expired

What this patent protects

The present invention relates to a protein encapsulated by an encapsulating organic compound (EOC) or proteophore wherein the protein and the encapsulating organic compound are present in 1:1 stoichiometry. In one embodiment of the present invention, the encapsulation is re…

USPTO Abstract

The present invention relates to a protein encapsulated by an encapsulating organic compound (EOC) or proteophore wherein the protein and the encapsulating organic compound are present in 1:1 stoichiometry. In one embodiment of the present invention, the encapsulation is realized by an EOC protein inclusion compound EPIC according to the formula (I) in which the EMCs are connected to each other by one branching unit B under formation of a cavity which is vertically and horizontally open    and wherein the symbols have the following meanings: B: branching unit containing at least one branching center Bc and at least two branching functional groups Bfg connected to or capable of reacting with an encapsulating molecular chain EMC; EMC: encapsulating molecular chain; L: linker containing at least one functional group Lfg which is connected to the protein P or capable of connecting with functional groups present on the protein P under the formation of a chemical bond; 1: 1, 2, 3, 4, 5, 6, 7, 8 or 9; P: pharmacologically active protein. In a further embodiment of the present invention, the encapsulation is realized by a macrocycle-protein inclusion compound MPIC according to the formula (IX) containing a protein P and a macrocyclic structure, and wherein the symbols have the meanings given above for formula (I). The EMCs can comprise substituents (capping groups), which can result in dendritic structures. The encapsulation assures a controlled release of a protein.

Drugs covered by this patent

Patent Metadata

Patent number
EP1525890A1
Jurisdiction
EP
Classification
Expires
2005-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Ascendis Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.